The Cure Starts Now follows an extensive grant approval process to ensure your dollars make the biggest impact to homerun cancer research. Take comfort in knowing that The Cure Starts Now only funds: research that follows our mission, research that is non-duplicative, and research that is financially sound.


The Cure Starts Now has funded $24,388,300 (USD) in pediatric brain cancer research in partnership with the DIPG / DMG Collaborative. This includes 156 grants at over 100 hospitals in 29 countries.




Oncoceutics ONC201 - $83,333

Amount
$83,333.00
Date
October 2018

Expansion of the ONC201 Compassionate Use.

The Institute of Cancer Research - $100,000

Amount
$100,000.00
Date
October 2018

Short-pulse Ultrasound Delivery of Panobinostat for the Treatment of Diffuse Intrinsic Gliomas in Children

The Institute of Cancer Research - $106,647

Amount
$106,647.00
Date
October 2018

A Mouse Model of HIST1H3B/ACVR1 Mutant DIPG.

Johns Hopkins Children's Center - $50,000

Amount
$50,000.00
Date
July 2018

Using Zebrafish to Accelerate DIPG Drug Development.

Funding of PBTCF 2018: PBTC-058 - $16,800

Amount
$16,800.00
Date
January 2018

PBTC-058: Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients with Recurrent Medulloblastoma and Ependymoma

The Campbell Family Institute for Cancer Research - $100,000

Amount
$100,000.00
Date
October 2017

Defining the molecular mechanisms of DIPG development and progression to uncover novel therapeutic targets

Institute of Cancer Research - $102,432

Amount
$102,432.00
Date
October 2017

Combinational strategies alongside ACVR1 inhibition in DIPG

The Regents of the University of California - $70,000

Amount
$70,000.00
Date
October 2017

An Open Label Single Arm Phase I/II study of MTX110 delivered by convection-enhanced delivery (CED) in patients with diffuse intrinsic pontine glioma (DIPG) previously treated with external beam radiation therapy

The Hospital for Sick Children - $100,560

Amount
$100,560.00
Date
October 2017

MRI Guided Focused Ultrasound: Towards Clinical Translation in Diffuse Intrinsic Pontine Glioma (DIPG)

Texas Children's Hospital and Ann & Robert H. Lurie Children's Hospital of Chicago - $200,000

Amount
$200,000.00
Date
October 2017

Targeting DIPG through Combining a Super-activator (MCB-613) of Steroid Receptor Co-activators with Radiation.

Gustave Roussy - $101,868

Amount
$101,868.00
Date
October 2017

Elucidating the underlying mechanisms of radio resistance at diagnosis and relapse in DIPG

Ospedale Pediatrico Bambino Gesu - $98,987

Amount
$98,987.00
Date
October 2017

Investigating the role of DIPG-derived exosomes in tumor growth and invasion

Memorial Sloan Kettering Cancer Center - $100,000

Amount
$100,000.00
Date
October 2017

Targeting EZH2 as a therapeutic strategy in DIPG

Dana-Farber Cancer Institute - $82,863

Amount
$82,863.00
Date
October 2017

Defining the Cellular Architecture of Diffuse Intrinsic Pontine Glioma through Large-Scale Single-cell RNA-sequencing analyses

The Hospital of Sick Children - $162,828

Amount
$162,828.00
Date
October 2017

Targeting DIPG through pharmacological activation of mitochondrial biogenesis: an in vitro and in vivo preclinical study